16 January 2017
Pavel Lobachev, the director of the Budker Institute of Nuclear Physics, said that his institute will do the accelerator in order to begin clinical trials of the latest boron neutron capture therapy (BNCT) by 2020.
NOVOSIBIRSK (Sputnik) — Russian scientists are planning to begin clinical trials of the latest boron neutron capture therapy (BNCT), which aims to destroy cancer tumors by a particle accelerator, by 2020, Pavel Lobachev, the director of the Budker Institute of Nuclear Physics, said Monday.
"The task is to renovate the building [for the trials] with the help of The Federal Agency for Scientific Organizations, we [Budker Institute] will do the accelerator, so that we could begin clinical trials by 2020," Lobachev told journalists.
The director of the Institute of Nuclear Physics also said that in the past year the scientists have been able to reinforce the particle accelerator's capacity to the level that allows to carry out the trials. According to Lobachev, the new goal was to perfect the delivery of the boron compounds into the malignant tumors.
Lobachev expressed hope that BNCT program would launch in 2017 and added that it had united a number of Russian research institutes specializing in chemistry, biology, physics and medicine.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024